Blisibimod Shows Some Promise for Moderate to Severe SLEBlisibimod Shows Some Promise for Moderate to Severe SLE

Blisibimod, an inhibitor of B cell-activating factor (BAFF), improves some endpoints in patients with systemic lupus erythematosus, especially those with more severe disease, according to results from the phase 2 PEARL-SC study. Reuters Health Information

Source: Medscape Medical News Headlines - May 16, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news